In this episode, ⁠Adam Torres⁠ interviews ⁠Jacob Glanville⁠, CEO of Centivax, Inc., about the company’s mission to develop universal vaccines that work across all strains of infectious diseases. Jacob shares how his upbringing and scientific background led him to build a biotech company focused on long-term global health, improved patient outcomes, and next-generation immunity solutions.

About ⁠Jake Glanville⁠

Jacob Glanville is a serial entrepreneur, and computational immuno-engineer. He built and sold his first company Distributed Bio from founding in March of 2012 to a 104M dollar sale to Charles River Laboratories in December of 2020. During that period, he developed the core business model, the research teams, and the technologies that enabled Distributed Bio to become profitable without investment. As part of the acquisition agreement, he founded Centivax Inc and spun-out his assets in COVID-19 therapeutics, broad-spectrum vaccines, antivenom antibodies, anti-wound pathogen antibodies, anti-CXCR5 autoimmunity therapeutics, and blood-brain barrier translation technologies into Centivax, where he is now CEO.

Follow Adam on Instagram at ⁠https://www.instagram.com/askadamtorres/⁠ for up to date information on book releases and tour schedule.

Apply to be a guest on our podcast:

⁠https://missionmatters.lpages.co/podcastguest/⁠

Visit our website:

⁠https://missionmatters.com/⁠

More FREE content from Mission Matters here: ⁠https://linktr.ee/missionmattersmedia⁠

Learn more about your ad choices. Visit podcastchoices.com/adchoices